skip to main content
Idioma:
Tipo de recurso Mostra resultados com: Mostra resultados com: Índice

Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning

Anand, Sarah ; Thomas, Samantha ; Corbet, Kelly ; Gasparetto, Cristina ; Long, Gwynn D. ; Lopez, Richard ; Morris, Ashley K. ; Rizzieri, David A. ; Sullivan, Keith M. ; Sung, Anthony D. ; Sarantopoulos, Stefanie ; Chao, Nelson J. ; Horwitz, Mitchell E.

Biology of blood and marrow transplantation, 2017-11, Vol.23 (11), p.1949-1954

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
  • Título:
    Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning
  • Autor: Anand, Sarah ; Thomas, Samantha ; Corbet, Kelly ; Gasparetto, Cristina ; Long, Gwynn D. ; Lopez, Richard ; Morris, Ashley K. ; Rizzieri, David A. ; Sullivan, Keith M. ; Sung, Anthony D. ; Sarantopoulos, Stefanie ; Chao, Nelson J. ; Horwitz, Mitchell E.
  • Assuntos: Transplantation conditioning ; Umbilical cord blood transplantation
  • É parte de: Biology of blood and marrow transplantation, 2017-11, Vol.23 (11), p.1949-1954
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
  • Descrição: •UCB transplant with thiotepa, TBI, and fludarabine provides reliable engraftment.•Early treatment-related mortality is also reduced after this regimen.•Thiotepa, TBI, and fludarabine are an effective alternate myeloablative regimen. Treatment-related mortality (TRM) remains elevated in adult patients undergoing umbilical cord blood transplantation (UCBT), including an early rise in TRM suggestive of excessive toxicity associated with the standard myeloablative total body irradiation (TBI), fludarabine, and cyclophosphamide regimen. In an attempt to reduce regimen-related toxicity, we previously studied a modified myeloablative regimen with TBI (1350 cGy) and fludarabine (160 mg/m2); TRM was decreased, but neutrophil engraftment was suboptimal. Therefore, to improve engraftment while still minimizing regimen-related toxicity, we piloted a myeloablative regimen with the addition of thiotepa (10 mg/kg) to TBI and fludarabine conditioning. Thirty-one adult patients (median age, 46 years; range, 19 to 65) with hematologic malignancies (acute leukemia/myelodysplastic syndrome, 77%; lymphoid malignancy, 23%) underwent single (n = 1) or double (n = 30) UCBT from 2010 to 2015 at our institution. The cumulative incidence of neutrophil engraftment was 90% (95% confidence interval [CI], 70% to 97%) by 60 days, with a median time to engraftment of 21 days (95% CI, 19 to 26). The cumulative incidence of platelet engraftment was 77% (95% CI, 57% to 89%) by 100 days, with a median time to engraftment of 47 days (95% CI, 37 to 73). Cumulative incidences of grades II to IV and grades III to IV acute graft-versus-host disease (GVHD) at day 100 were 45% (95% CI, 27% to 62%) and 10% (95% CI, 2% to 23%), respectively. The overall incidence of chronic GVHD at 2 years was 40% (95% CI, 22% to 57%), with 17% of patients (95% CI, 6% to 33%) experiencing moderate to severe chronic GVHD by 2 years. TRM at 180 days was 13% (95% CI, 4% to 27%), at 1 year 24% (95% CI, 10% to 41%), and at 3 years 30% (95% CI, 13% to 49%). Relapse at 1 year was 13% (95% CI, 4% to 27%) and at 3 years 19% (95% CI, 6% to 38%). With a median follow-up of 35.5 months (95% CI, 12.7 to 52.2), disease-free and overall survival at 3 years were 51% (95% CI, 29% to 69%) and 57% (95% CI, 36% to 73%), respectively. This regimen represents a reasonable alternative to myeloablative conditioning with TBI, fludarabine, and cyclophosphamide and warrants further study.
  • Editor: United States: Elsevier Inc
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.